BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting

BioCryst announced new clinical data and real-world evidence for ORLADEYO (berotralstat), its oral prophylactic therapy for hereditary angioedema (HAE), showing consistent reductions in HAE attack burden and healthcare utilization. The company also presented post hoc analysis from the Phase 1b/2 ALPHA-STAR study of investigational navenibart, a long-acting monoclonal antibody plasma kallikrein inhibitor, demonstrating consistent attack rate reductions across patient subgroups and supporting ongoing Phase 3 evaluation.